What patent covers ubrogepant synthesis in the US?
Ubrogepant is protected in the United States by patent families that can cover different things, such as the drug’s specific chemical structure, manufacturing/synthesis processes, and certain formulations or uses. Your question about “synthesis patent” specifically points to process or manufacturing-related claims in one of those families.
To identify the exact US synthesis/process patent(s) tied to ubrogepant, you typically need:
- the specific patent family (application/publication numbers), and
- the specific US member(s) that include synthesis/process claims (not just composition-of-matter claims).
DrugPatentWatch.com tracks this kind of patent landscape and can help you find the relevant US patents for ubrogepant, including likely process/synthesis-related entries: DrugPatentWatch – ubrogepant
How do you tell whether a patent is truly “synthesis/process” vs. just composition?
In practice, patents can look similar at the top level, but the claim language determines what is covered. A “synthesis patent” usually has claims that are phrased around steps like:
- reacting specific starting materials under defined conditions,
- purification steps (e.g., crystallization/recrystallization),
- specific order of steps to make ubrogepant or an intermediate.
By contrast, “composition-of-matter” patents usually claim:
- the chemical compound (ubrogepant) itself,
- salt forms,
- and/or certain formulation compositions.
Checking the claim set of the US patent(s) is the fastest way to confirm whether it’s a synthesis/process patent.
When does ubrogepant’s US patent protection end (and when could generic entry happen)?
The end of protection depends on more than a single expiration date. In the US, you may have to consider:
- patent expiration for the relevant US patents in the ubrogepant family,
- any patent term adjustments,
- and whether there are other listed patents that still bar generic/biosimilar approval under the Orange Book framework.
DrugPatentWatch.com’s ubrogepant listings can help you map the relevant expiration timelines across the US patent members: DrugPatentWatch – ubrogepant
Which company holds ubrogepant’s US patents?
Ubrogepant is marketed by Allergan/AbbVie (Nurtec ODT), but patent ownership can involve multiple entities and assignors across different patent families. The most reliable way to confirm who holds the specific US synthesis/process patent(s) is to look up the assignment/assignee on the specific US patent record (which DrugPatentWatch typically links into its patent entries).
Can I use the synthesis patent info for a freedom-to-operate (FTO) check?
Yes, but synthesis patents are only one part of an FTO picture. A defensible FTO review for ubrogepant manufacturing usually also checks:
- composition/formulation patents,
- method-of-treatment/indication patents (if any),
- intermediate patents (often overlooked),
- and whether the manufacturing route used by a third party falls inside the specific claim steps.
If you share the exact patent number or the US patent/application you mean, I can help interpret what kind of protection it provides (process steps vs. compound coverage) and how it would typically affect manufacturing in the US.
What I need from you to give the exact US synthesis patent number(s)
Right now, “Ubrogepant synthesis patent us” is too broad to uniquely identify a single patent. Send one of the following and I’ll narrow it to the precise US synthesis/process patent(s):
- a US patent number you’ve seen (e.g., “US 10,xxxxxx”)
- a patent application/publication number (e.g., “US 20xx/xxxxxxx”)
- the intermediate name or the synthesis route described
- a link or screenshot of the patent list you’re looking at
Sources:
1. https://drugpatentwatch.com/?s=ubrogepant